COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study

被引：0
|
作者：
Allsup, David [1 ,2 ]
Howard, Dena [3 ]
Emmerson, Jake [3 ]
Hockaday, Anna [3 ]
Rawstron, Andy [4 ]
Oughton, Jamie B. [3 ]
Bloor, Adrian [5 ]
Phillips, David [3 ]
Nathwani, Amit [6 ]
Paneesha, Shankara [7 ]
Turner, Deborah [8 ]
Munir, Talha [9 ]
Hillmen, Peter [9 ]
机构：
[1] Hull Univ Teaching Hosp, Haematol, Kingston Upon Hull, Yorks, England
[2] Hull York Med Sch, Ctr Atherothrombosis & Metab Dis, Kingston Upon Hull, N Humberside, England
[3] Univ Leeds, Clin Trials Res Unit, Leeds, W Yorkshire, England
[4] St James Univ Hosp, Leeds, W Yorkshire, England
[5] Christie NHS Fdn Trust, Manchester, Lancs, England
[6] Univ Coll London Hosp, London, England
[7] Birmingham Heartlands Hosp, Birmingham, W Midlands, England
[8] Torbay Dist Hosp, Torquay, England
[9] St James Univ Hosp, St James Inst Oncol, Leeds, W Yorkshire, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 194卷 / 03期
关键词：
chronic lymphocytic leukaemia; chemotherapy; clinical trial; monoclonal antibody; minimal residual disease; FLUDARABINE; CYCLOPHOSPHAMIDE; CHLORAMBUCIL; RITUXIMAB;
D O I：
10.1111/bjh.17526
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：646 / 650
页数：5
相关论文
共 50 条
  • [31] Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted)
    Hillmen, P.
    Pettitt, A.
    Schuh, A.
    Milligan, D.
    Bowles, K.
    Bareford, D.
    Riaz, J. M.
    Follows, G.
    Rule, S.
    Wallis, J.
    Gribben, J.
    Noble, R.
    Pocock, C.
    Lisby, S.
    Carey, J.
    Gupta, I.
    Chang, C. N.
    McKeown, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 : 19 - 20
  • [32] Haematologic and immunologic function and patient-reported outcomes for the phase 3 RESONATE™ study of ibrutinib versus ofatumumab in relapsed/refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma
    Munir, T.
    Barrientos, J. C.
    O'Brien, S.
    Brown, J. R.
    Kay, N. E.
    Reddy, N. M.
    Coutre, S.
    Tam, C.
    Mulligan, S.
    Jaeger, U.
    Devereux, S.
    Pocock, C.
    Robak, T.
    Schuster, S. J.
    Schuh, A.
    Gill, D.
    Bloor, A.
    Dearden, C.
    Moreno, C.
    Cull, G.
    Hamblin, M.
    Jones, J. A.
    Kierschniak, T.
    Eckert, K.
    Suzuki, S.
    Hsu, E.
    James, D.
    Byrd, J. C.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 70 - 70
  • [33] Ofatumumab combined with chlorambucil for previously untreated chronic lymphocytic leukemia: a phase I/II, open-label study in Japan
    Kiyohiko Hatake
    Michinori Ogura
    Kohichi Takada
    Masafumi Taniwaki
    Fanghong Zhang
    Taizo Fujita
    Kiyoshi Ando
    International Journal of Hematology, 2017, 106 : 240 - 247
  • [34] Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
    Pabst, Thomas
    Papayannidis, Cristina
    Demirkan, Fatih
    Doronin, Vadim
    Fogliatto, Laura M.
    Guttke, Christina
    Gyan, Emmanuel
    Hamad, Nada
    Herrera, Pilar
    Hultberg, Anna
    Jacobs, Julie
    Johnson, Amy J.
    Langlois, Angelique
    Ma, Xuewen
    Martinelli, Giovanni
    Arnan, Montserrat
    Mueller, Rouven
    Nottage, Kerri
    Ofran, Yishai
    Ozcan, Muhit
    Samoilova, Olga
    Tolbert, Jaszianne A.
    Trudel, Geralyn C.
    Xiu, Liang
    Vey, Norbert
    Wei, Andrew
    LANCET HAEMATOLOGY, 2023, 10 (11): : E902 - E912
  • [35] Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial
    Howard, Dena R.
    Munir, Talha
    McParland, Lucy
    Rawstron, Andy C.
    Chalmers, Anna
    Gregory, Walter M.
    O'Dwyer, John L.
    Smith, Alison
    Longo, Roberta
    Varghese, Abraham
    Smith, Alexandra
    Hillmen, Peter
    HEALTH TECHNOLOGY ASSESSMENT, 2017, 21 (28) : XXV - +
  • [36] Phase II study of octreotide plus standard chemotherapy in the treatment of small cell lung cancer
    Decatris, MP
    Thomas, A
    Fresco, L
    Jeffries, K
    Conray, S
    Benghiat, A
    O'Byrne, KJ
    BRITISH JOURNAL OF CANCER, 2000, 83 : 42 - 42
  • [37] A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS
    Montillo, M.
    Rossi, D.
    Motta, M.
    Quaresmini, G.
    Rossi, M.
    Coscia, M.
    Anastasia, A.
    Rossini, F.
    Cortellezzi, A.
    Nador, G.
    Scarfo, L.
    Cairoli, R.
    Frustaci, A. M.
    Dal Ceggio, D.
    Picardi, P.
    De Paoli, L.
    Orlandi, E.
    Rambaldi, A.
    Morra, E.
    Massaia, M.
    Tedeschi, A.
    HAEMATOLOGICA, 2014, 99 : 61 - 62
  • [38] Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia
    Osterborg, Anders
    Udvardy, Miklos
    Zaritskey, Andrey
    Andersson, Per-Ola
    Grosicki, Sebastian
    Mazur, Grzegorz
    Kaplan, Polina
    Steurer, Michael
    Schuh, Anna
    Montillo, Marco
    Kryachok, Iryna
    Middeke, Jan Moritz
    Kulyaba, Yaroslav
    Rekhtman, Grygoriy
    Gorczyca, Michele
    Daly, Siobhan
    Chang, Chai-Ni
    Lisby, Steen
    Gupta, Ira
    LEUKEMIA & LYMPHOMA, 2016, 57 (09) : 2037 - 2046
  • [39] Early Results of a Phase II Study of Ofatumumab As Front-Line Treatment in Elderly, Unfit Patients with Chronic Lymphocytic Leukemia (CLL)
    Ciccone, Maria
    Vitale, Candida
    Hinojosa, Christina
    Keating, Michael J.
    Pemmaraju, Naveen
    O'Brien, Susan
    Burger, Jan A.
    Thomas, Deborah A.
    Kantarjian, Hagop M.
    Strati, Paolo
    Wierda, William G.
    Ferrajoli, Alessandra
    BLOOD, 2014, 124 (21)
  • [40] DASATINIB PLUS FLUDARABINE IN PATIENTS WITH REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A MULTICENTER PHASE II STUDY
    Kater, A.
    Spiering, M.
    Lui, R.
    Beckers, M.
    Tonino, S.
    Doorduijn, J.
    Daenen, S.
    Luijks, D.
    Eldering, E.
    van Oers, M.
    HAEMATOLOGICA, 2012, 97 : 304 - 304
12345